ASSESSMENT OF BLOOD MARKERS AFTER RADIONUCLIDE THERAPY FOR OSTEOGENIC METASTASIS OF KIDNEY AND PROSTATE CANCER . Wor.Bul.Pub.Helt. 2022, 12, 66-69.